Infinity Pharmaceuticals (NASDAQ:INFI) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Infinity Pharmaceuticals (NASDAQ:INFI – Free Report) in a research note published on Sunday. The firm issued a hold rating on the biotechnology company’s stock. Infinity Pharmaceuticals Price Performance Infinity Pharmaceuticals has a twelve month low of $0.01 and a twelve month high of $0.01. The company has a market […]

Related Keywords

Adeleneq Perkins , ,Mirabella Financial Services ,Infinity Pharmaceuticals ,Securities Exchange Commission ,Millennium Management ,Infinity Pharmaceuticals Inc ,News Ratings For Infinity Pharmaceuticals Daily ,Charles Schwab Investment Management Inc ,Infinity Pharmaceuticals Price Performance ,Renaissance Technologies ,Free Report ,Get Free Report ,Director Adelene ,Exchange Commission ,Schwab Investment Management ,Street Corp ,Financial Services ,Infinity Pharmaceuticals Daily ,Nasdaq Infi ,Infi ,Medical ,45665g30 ,Initiated Coverage ,Stocknews Com ,